T. T. Hansel

This book provides a state-of-the-art account by academic respiratory physicians and senior pharmaceutical industry personnel on the development of new drugs for asthma, allergy and COPD. It contains 80 chapters of highly condensed information, presented in an attractive, reader-friendly format with much use of tables, figures and diagrams. In addition to summarizing the diverse range of current approaches, this handbook also looks into the future, considering many topics that are promising, but have only emerged in the last few years. Developments within established drug categories such as beta-2-agonists, steroids and leukotriene antagonists are also reviewed. Never before has a single book brought together so many pharmaceutical drug developers sharing their experience on such a wide range of respiratory topics.

"This volume provides state-of-the-art information on the pathophysiology of COPD, including an outlook on potential new therapies. It is of interest to researchers and health professionals involved in the care of patients with COPD, as well as scientists seeking new therapies in the pharmaceutical industry."--BOOK JACKET.